$10.79
-0.20 (-1.82%)
Open$10.92
Previous Close$10.99
Day High$11.22
Day Low$10.57
52W High$12.41
52W Low$3.94
Volume—
Avg Volume466.6K
Market Cap1.49B
P/E Ratio—
EPS$-1.61
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+615.9% upside
Current
$10.79
$10.79
Target
$77.25
$77.25
$52.47
$77.25 avg
$103.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.60M | 83.53M | 330.72M |
| Net Income | -222,235,143 | -305,968,530 | -35,950,365 |
| Profit Margin | -407.0% | -386.7% | -10.9% |
| EBITDA | -195,535,368 | -284,164,906 | -62,958,224 |
| Free Cash Flow | — | — | -53,039,983 |
| Rev Growth | -34.6% | -34.6% | -2.7% |
| Debt/Equity | 0.03 | 0.03 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |